ONLINE RESOURCE 1

Real-world experience of carglumic acid for methylmalonic and propionic acidurias: an interim analysis of the multicentre, observational PROTECT study

Authors: Sufin Yap*, Delphine Lamireau, Francois Feillet, Angeles Ruiz Gomez, James Davison, Trine Tangeraas, Vincenzo Giordano

*Corresponding author: Sufin Yap, PhD

Department of Inherited Metabolic Diseases, Sheffield Children's Hospital, Western Bank, Sheffield, S10 2TH, United Kingdom.

Tel: +44 114 2717000; **Email:** <u>sufin.yap@nhs.net</u>

Fig. 1 Duration of hospital stay during decompensation events.

Panel (a) shows the duration of hospitalisation during the last decompensation event before initiating carglumic acid treatment and during the first decompensation event after initiating this treatment; panel (b) shows the mean duration of all decompensation events during both periods (pre- and post-carglumic acid treatment initiation).

Data are only for patients who had decompensation events both before and after treatment with carglumic acid. MMA methylmalonic aciduria, PA propionic aciduria



